Double-hit immunotherapy boosts melanoma survival

This is a UK news story, published by Guardian.

UK news

For more UK news, you can click here:

more UK news

biology news

For more biology news, you can click here:

more biology news

Guardian news

For more news from Guardian, you can click here:

more news from Guardian

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best science news, business news, entertainment news, and much more. If you like biology news, you might also like this article about

advanced melanoma skin cancer

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest melanoma news, skin cancer news, biology news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

advanced melanoma

Guardian

•

Double drug treatment raises survival rate for half of advanced melanoma cases to 10 years

Summary

Nutrition label

78% Informative

More than half of people diagnosed with advanced melanoma now survive for at least 10 years when they receive a double hit of immunotherapy drugs, a trial has found.

15 years ago , only one in 20 patients with advanced skin cancer survived for five years , with many dying within six to nine months of diagnosis.

More than 20,000 people are expected to be diagnosed with melanoma in the UK this year .

VR Score

Informative language

Neutral language

Article tone

informal

Language

English

Language complexity

Offensive language

not offensive